- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Royalty Pharma Plc
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
8.44%
1.64%
News
Connect
People who are active on baraka tribe community
Stock Analysis
last close
$37.5
1-mo return
3.3%
3-mo return
-7.1%
avg daily vol.
1.25M
52-week high
53.23
52-week low
34.8
market cap.
$16.4B
forward pe
12.6
annual div.
0.68
roe
19.6%
ltg forecast
11.9%
dividend yield
1.81%
annual rev.
$2.2B
inst own.
59.1%
